Use patterns of topical calcineurin inhibitors (TCIs) were reviewed in 8,015 patients with atopic dermatitis (AD) where patients with mild-to-moderate disease were required to use pimecrolimus for at least six weeks out of the six months preceding enrollment.
Pediatric Atopic Dermatitis: Topical Calcineurin Inhibitors
